ESPR Stock Price, Chart, Stats & News
Esperion Therapeutics Inc (ESPR) is a dividend-paying stock with a current dividend yield of 99.37% as of Jul 13, 2026. It pays $3.16 per share over the trailing twelve months and distributes annually.
ESPR chart
Fundamentals
Gross margin | 64.44% |
Operating margin | 14.95% |
Pretax margin | -5.17% |
Net margin | -5.63% |
Effective tax rate | -8.83% |
ROA | -4.87% |
ROE | 5.62% |
D/E | -1.81x |
Interest coverage ratio | 0.71x |
ESPR valuation
P/E | – |
P/S | 1.41x |
P/B | -2.15x |
P/CF | -49.53x |
P/FCF | -44.15x |
P/OCF | -49.53x |
PEG | -0.39x |
EV multiple | 3.02x |
About
Esperion Therapeutics, Inc. operates as a pharmaceutical firm, concentrating on the development and commercialization of treatments for individuals with high levels of low-density lipoprotein (LDL) cholesterol. The company's flagship pharmaceutical products are NEXLETOL (bempedoic acid) and NEXLIZET (a tablet combining bempedoic acid and ezetimibe), prescribed for managing conditions such as atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. In addition, Esperion maintains a licensing and collaborative partnership with Daiichi Sankyo Europe GmbH, alongside an agreement with Serometrix to acquire rights to an oral, small molecule PCSK9 inhibitor program.
Related lists
Similar securities
Based on sector and market capitalization
